机构：[1]Department of Medical Oncology, Beijing Chest Hospital, Beijing Tuberculosis and Thoracic Tumor Research Institute, Capital Medical University, Beijing, China.[2]Department of Respiratory Medicine, Qingyang People's Hospital, Gansu, China.[3]Department of Thoracic Surgery, Xuanwu Hospital, Capital Medical University, Beijing, China.外科系统胸外科首都医科大学宣武医院[4]Department of Pathology, Beijing Chest Hospital, Beijing Tuberculosis and Thoracic Tumor Research Institute, Capital Medical University, Beijing, China.[5]The Cancer Center, Union Hospital, Fujian Medical Center, Fuzhou, China.[6]Immunotherapy Research and Development, CreMab Biopharma, Inc, Fuzhou, China.[7]The Immunotherapy Institute, Fujian Medical University, Fuzhou, China.[8]Department of Otolaryngology, Cancer Center, University of Minnesota Medical School, Minnesota, United States.[9]Department of Central Laboratory, Beijing Chest Hospital, Beijing Tuberculosis and Thoracic Tumor Research Institute, Capital Medical University, Beijing, China.
Siglec-15 (S15) is another important mechanism of tumor immune escape besides the PD-L1/PD-1 pathway and represents a new kind of immune checkpoint inhibitor. However, the associations of tumor Siglec-15 expression with clinicopathological characteristics and outcomes of non-small cell lung cancer (NSCLC), and tumor-infiltrating lymphocytes (TILs) in a tumor microenvironment (TME) have so far been unclear. A total of 324 NSCLC surgical samples on tumor microarray were used in this study for investigating the association of S15 expression with clinicopathological characteristics and overall survival rate (OS) as well as correlation with TILs using multiplex immunofluorescence staining and PD-L1. Results showed that the expression of S15 in squamous cell carcinoma was significantly higher than that in adenocarcinoma. S15 expression was positively correlated with CD8+ T cell density in the stroma. The expression rate of PD-L1 in lung squamous cell carcinoma was higher than that in lung adenocarcinoma. S15 expression was not associated with the prognosis of early NSCLC. The pathological mechanism of the co-expression of S15 and PD-L1 in resectable NSCLC remains to be further studied.
基金：
This study was supported by the
Lung Cancer Project from Beijing Municipal Health Commission 362 (2017-2019).
第一作者机构：[1]Department of Medical Oncology, Beijing Chest Hospital, Beijing Tuberculosis and Thoracic Tumor Research Institute, Capital Medical University, Beijing, China.[2]Department of Respiratory Medicine, Qingyang People's Hospital, Gansu, China.
共同第一作者：
通讯作者：
推荐引用方式(GB/T 7714)：
Hao J Q,Nong J Y,Zhao D,et al.The significance of Siglec-15 expression in resectable non-small cell lung cancer.[J].NEOPLASMA.2020,67(6):1214-+.doi:10.4149/neo_2020_200220N161.
APA：
Hao J Q,Nong J Y,Zhao D,Li H Y,Su D...&Wang J H.(2020).The significance of Siglec-15 expression in resectable non-small cell lung cancer..NEOPLASMA,67,(6)
MLA：
Hao J Q,et al."The significance of Siglec-15 expression in resectable non-small cell lung cancer.".NEOPLASMA 67..6(2020):1214-+
